Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | CA4 | P22748 | 3/20 | 0.65 |
| ▸ | CA6 | P23280 | 3/20 | 0.65 |
| ▸ | CA5A | P35218 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 3/20 | 0.65 |
| ▸ | CA9 | Q16790 | 3/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.65 |
| ▸ | F13A1 | P00488 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | THPO | P40225 | 2/20 | 0.65 |
| ▸ | CASP2 | P42575 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | CA3 | P07451 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318593 | 1.00 | CA12 (0.65) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25321416 | 1.00 | CA12 (0.65) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25318754 | 1.00 | CA12 (0.65) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25320103 | 1.00 | CA12 (0.65) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25317086 | 0.97 | CA12 (0.68) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25318736 | 0.97 | CA12 (0.68) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25318726 | 0.97 | CA12 (0.68) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25315826 | 0.97 | CA12 (0.68) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25318648 | 0.97 | CA12 (0.68) | CA12CA2CA4CA6CA5A | |
| SCHEMBL10363424 | 0.97 | CA12 (0.68) | CA12CA2CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | CD63, NIBAN2, ZRANB2 | CA12 944/4885CA2 3531/4885CA4 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.